CJC 1295 + IPAMORELIN

Summary

The CJC-1295 without DAC + Ipamorelin blend is researched for its role in the pulsatile release of the body's own growth hormone. It combines in a single vial a GHRH analog and a selective ghrelin receptor agonist: two different pathways that converge on the pituitary gland.

What is it researched for?

• • Pulsatile secretion of endogenous GH
• • GH / IGF-1 axis
• • Body composition and recovery
• • Deep sleep quality

Cycle and break

Mechanism of action

CJC-1295 without DAC — GHRH analog

A modified version of the GRF(1-29) fragment that binds to the pituitary GHRH receptor and amplifies the amplitude of the GH pulse. Without DAC technology its half-life is short, so it respects the natural pulsatile pattern.

Ipamorelin — selective ghrelin agonist

A pentapeptide that activates the GHS-R1a receptor. Its distinguishing feature is selectivity: unlike classic GHRPs, it barely raises cortisol or prolactin.

Synergy at the pituitary

Each component acts on a different receptor. When combined, an additive effect on the GH pulse is studied that is greater than that of either one alone.

Scientific evidence

CJC-1295: Studies with the GRF(1-29) fragment document dose-dependent increases in GH and IGF-1 in healthy subjects.

Ipamorelin: Described in the literature as the most selective secretagogue in its family, with a clean endocrine profile.

Synergy: The GHRH + GHRP combination is a classic in research on the somatotropic axis. An honest note: there are no controlled human studies of this specific combined formulation.

Product use

This blend brings together the two complementary secretagogue mechanisms in a single reference material for in vitro and laboratory research. At Peptido BioGenetic we offer it with high-purity components and a certificate of analysis (COA) available on request.

⚠️ Product intended exclusively for research and laboratory use. Not for human or veterinary consumption.